Sleep Health

Military Health System: Obesity Drugs Proven Cost-Effective

Obesity drugs semaglutide and tirzepatide proven cost-effective for U.S. Military Health System, treating obesity and related conditions.

Military Health System: Obesity Drugs Proven Cost-Effective

Two medications, semaglutide and tirzepatide, have been found to be cost-effective at prices negotiated for the U.S. Military Health System, according to a recent analysis presented at ObesityWeek.

The study, led by Taylor Neuman, MD, internal medicine physician and head of the metabolic health and weight management service at Walter Reed National Military Medical Center, focused on the cost-effectiveness of these drugs in treating obesity and related conditions within the military population.

Rising Obesity Rates in the Military

Obesity has become a growing concern within the U.S. Military Health System, which covers over 9 million active-duty service members and their families. Taylor Neuman noted that obesity in the active-duty population rose from 8% in 2002 to 23% in 2023, and the entire Military Health System now has a prevalence of 42% overweight and 26% obesity.

This trend has led to a significant increase in the use of obesity medications, with the prevalence rising from 0.56% in 2018-2022 to 5.5% in 2023-2024.

Cost-Effectiveness Analysis

The analysis utilized a Markov cohort model to simulate the onset of various obesity-related conditions, including type 2 diabetes, cardiovascular disease, and obstructive sleep apnea. The model compared the cost-effectiveness of injectable semaglutide, injectable tirzepatide, and oral semaglutide against lifestyle modifications alone.

The study included a large eligible population of 354,978 adults aged 18 to 64 and 17,688 adults aged 65 to 75, with a mean baseline BMI of 35.2 kg/m² and 35.4 kg/m², respectively.

The results showed that tirzepatide was the most cost-effective option for adults aged 18 to 64, with a total lifetime cost difference of $1,046 and an incremental cost-effectiveness ratio (ICER) of $698 per quality-adjusted life-year (QALY) gained. This is significantly lower than the willingness-to-pay threshold of $100,000 per QALY used in the analysis.

In comparison, injectable semaglutide and oral semaglutide had higher ICERs of $10,838 and $14,118, respectively, for the same age group.

For adults aged 65 to 75, tirzepatide still showed favorable results, with an ICER of $15,742, compared to $25,770 for injectable semaglutide and $35,873 for oral semaglutide.

The analysis also revealed that the medications would become fully dominant at lower annual prices, with tirzepatide requiring only a modest price reduction to meet the cost-effectiveness threshold.

Neuman said, “Obviously the number that jumps out the most is the ICER result estimate for tirzepatide in the younger group of $698 per QALY.”

Injectable semaglutide 7.2 mg was not included the analysis and could have produced different results from the other forms of semaglutide, he said.

In a sensitivity analysis, the researchers determined the biggest factors behind the ICER for tirzepatide in the younger population were the costs of treating type 2 diabetes, the incidence of type 2 diabetes and baseline BMI, he said.

In a break-even analysis, the researchers found that the medications would become fully dominant at the following annual prices: tirzepatide, $2,942.60 or less in adults aged 18 to 64 years and $1,906.10 or less in adults aged 65 to 75 years; injectable semaglutide, $2,299.90 or less in adults aged 18 to 64 years and $1,577.40 or less in adults aged 65 to 75 years; and oral semaglutide, $2,183.70 or less in adults aged 18 to 64 years and $1,312.50 or less in adults aged 65 to 75 years.

Detailed Cost Metrics and Sensitivity Analysis

The analysis provided detailed metrics for each medication across different age groups. For adults aged 18 to 64, tirzepatide prevented 0.27 heart attacks or strokes per person, with 1.5 quality-adjusted life-years (QALYs) gained. In contrast, injectable semaglutide prevented 0.25 such events and gained 1.13 QALYs, while oral semaglutide prevented 0.2 events and gained 1.01 QALYs.

For adults aged 65 to 75, tirzepatide prevented 0.05 heart attacks or strokes per person, with 0.7 QALYs gained.

Break-Even Analysis and Future Implications

Neuman said, “Tirzepatide … would only require a pretty low price reduction to meet that threshold.”

The study was presented at ObesityWeek in National Harbor, Maryland, with no relevant financial disclosures reported by Neuman.

Leave a Reply

Your email address will not be published. Required fields are marked *